Berotralstat (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Berotralstat" in English language version.

refsWebsite

Global rank English rank

3nih.gov

4^th place

2doi.org

2^nd place

2hres.ca

low place

2fda.gov

447^th place

338^th place

2europa.eu

68^th place

117^th place

1web.archive.org

1^st place

1globenewswire.com

2,614^th place

1,549^th place

1mayoclinic.org

1,610^th place

1,279^th place

1handle.net

102^nd place

76^th place

doi.org (Global: 2^nd place; English: 2^nd place)

Hwang JR, Hwang G, Johri A, Craig T (December 2019). "Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema". Immunotherapy. 11 (17): 1439–1444. doi:10.2217/imt-2019-0128. PMID 31635497.
Zuraw B, Lumry WR, Johnston DT, Aygören-Pürsün E, Banerji A, Bernstein JA, et al. (October 2020). "Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial". The Journal of Allergy and Clinical Immunology. 148 (1): 164–172.e9. doi:10.1016/j.jaci.2020.10.015. PMID 33098856.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Orladeyo EPAR". European Medicines Agency (EMA). 24 February 2021. Retrieved 12 July 2021.

ec.europa.eu

"Orladeyo Product information". Union Register of medicinal products. Retrieved 3 March 2023.

fda.gov (Global: 447^th place; English: 338^th place)

fda.gov

"Drug Trials Snapshot: Orladeyo". U.S. Food and Drug Administration. 3 December 2020. Archived from the original on 18 December 2020. Retrieved 25 December 2020. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Orladeyo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 December 2020.

globenewswire.com (Global: 2,614^th place; English: 1,549^th place)

"BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years". BioCryst Pharmaceuticals. 12 December 2025. Retrieved 13 December 2025 – via GlobeNewswire.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

"International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). 2019. hdl:10665/330879.

hres.ca (Global: low place; English: low place)

hpr-rps.hres.ca

"Summary Basis of Decision - Orladeyo". Health Canada. 23 October 2014. Retrieved 28 November 2022.

pdf.hres.ca

Product monograph hres.ca

mayoclinic.org (Global: 1,610^th place; English: 1,279^th place)

"Berotralstat (Oral Route) Side Effects - Mayo Clinic". www.mayoclinic.org. Retrieved 3 March 2021.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Hwang JR, Hwang G, Johri A, Craig T (December 2019). "Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema". Immunotherapy. 11 (17): 1439–1444. doi:10.2217/imt-2019-0128. PMID 31635497.
Zuraw B, Lumry WR, Johnston DT, Aygören-Pürsün E, Banerji A, Bernstein JA, et al. (October 2020). "Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial". The Journal of Allergy and Clinical Immunology. 148 (1): 164–172.e9. doi:10.1016/j.jaci.2020.10.015. PMID 33098856.

dailymed.nlm.nih.gov

"Orladeyo- berotralstat hydrochloride capsule". DailyMed. Retrieved 25 December 2020.

web.archive.org (Global: 1^st place; English: 1^st place)

"Drug Trials Snapshot: Orladeyo". U.S. Food and Drug Administration. 3 December 2020. Archived from the original on 18 December 2020. Retrieved 25 December 2020. This article incorporates text from this source, which is in the public domain.